Shire scores FDA nod for Mydayis, its latest Adderall iteration by Tracy Staton Wednesday, June 21, 2017 Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
Neos, facing critics, snags another pediatric ADHD nod by Carly Helfand Tuesday, June 20, 2017 There’s a new FDA-approved ADHD medication on the scene, and it’s one maker Neos Therapeutics thinks will put it in prime market position.
